Vaxcyte
PCVXNASDAQCarrier-sparing conjugate vaccine platform
Drafted with AI assistance from public sources and not individually reviewed by an editor; last updated 2026-04-09. Published by ClinicalInvestor. Educational analysis only. Read the editorial policy and disclosures.
text updated 2026-04-09, 222 days ago · archived: kept for reference, not maintained · where each field comes from
Key figures from SEC filings
Upcoming catalysts
Company-specific dates below are registry milestones or filings we have linked. For FDA decision dates site-wide, see the PDUFA calendar.
VAX-31 immunobridging: VAX-31 in Pneumococcal disease, adults 50+ — primary completion
2027-01
Registry milestone — the date data collection is scheduled to end, not when results are released. ClinicalTrials.gov
VAX-31 concomitant SIV: VAX-31 in Pneumococcal disease with influenza vaccine — primary completion
2027-03
Registry milestone — the date data collection is scheduled to end, not when results are released. ClinicalTrials.gov
VAX-31 infant dose-finding: VAX-31 in Pneumococcal disease, infants — primary completion
2027-12
Registry milestone — the date data collection is scheduled to end, not when results are released. ClinicalTrials.gov
Pipeline
| Drug | Indication | Phase | Expected data | |
|---|---|---|---|---|
| VAX-31 | adult invasive pneumococcal disease prevention | Phase 3 | Not disclosed | ▼ |
| VAX-24 | adult pneumococcal disease prevention | Phase 2 | Not disclosed | ▼ |
| VAX-A1 | group A strep prevention | Preclinical | Not disclosed | ▼ |
Analysis
Comparable companies
Sponsored
Get premium PCVX analysis on Seeking AlphaAffiliate link — we may earn a commission at no cost to you